In a co-graft tumour model, fibroblast-derived MCP-1 attenuated the effect of an MCP-1-neutralising antibody, while mutation of CCR2 in cancer cells significantly reduced tumour growth, indicating MCP-1 involvement in basal-like cell cancer progression [67]. The gene discussed is CCL2; the disease is cancer.